NCT01691989View on ClinicalTrials.gov

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

197

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

aleglitazar

150 mcg orally once a day for 26 weeks

DRUG

placebo

oral doses once a day for 26 weeks

Trial Locations (28)

1056

Buenos Aires

19067

Morrisville

20230

Aguascaliente

20817

Bethesda

23249

Richmond

27713

Durham

29651

Greer

30338

Atlanta

32216

Jacksonville

33716

St. Petersburg

34741

Kissimmee

38000

Celaya

44600

Guadalajara

44650

Guadalajara

46123

Avon

75230

Dallas

76000

Querétaro

90057

Los Angeles

91710

Chino

92161

San Diego

92701

Santa Ana

C1428DCO

Caba

S2000CXP

Rosario

Unknown

Bogotá

Floridablanca

Medellin-Antioquia

01010

Guatemala City

01014

Guatemala City

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01691989 - A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy | Biotech Hunter | Biotech Hunter